Serum TK1 is a more reliable marker than CEA and AFP for cancer screening in a study of 56,286 people
| Autor: | Yu Wang, Jin Li, Jiankun Shen, Shaoliang Dong, Ji Zhou, Xiaorong Jiang, Hongbo Ma, Ellen He, Haixia Yu, Sven Skog |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Oncology Adult Male Cancer Research medicine.medical_specialty Pathology Dot blot Sensitivity and Specificity Thymidine Kinase 03 medical and health sciences Young Adult 0302 clinical medicine Internal medicine Neoplasms Cancer screening Genetics medicine Biomarkers Tumor Humans Mass Screening Thymidine kinase 1 Health screening Cervix Early Detection of Cancer Aged Aged 80 and over business.industry Incidence Cancer General Medicine Middle Aged medicine.disease Carcinoembryonic Antigen 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis Population Surveillance Cohort Biomarker (medicine) Female alpha-Fetoproteins business Follow-Up Studies |
| Zdroj: | Cancer biomarkers : section A of Disease markers. 16(4) |
| ISSN: | 1875-8592 |
| Popis: | BACKGROUND: The World Health Organization (WHO) has estimated that the number of cancer patients will increase by about 70% during the next 25 years world-wide. To deal with this problem, WHO has suggested a focus on prevention of tumor incidence and health screening for early detection of people with tumors. OBJECTIVE: To investigate the use of thymidine kinase 1 (TK1), CEA and AFP in serum to discover people with malignant tumors through health cancer screening. METHODS: Of a cohort in 486,085 people of a routine health screening at the Health Centre, Fujun 180 Hospital, Quanzhou city, China, 56,286 people were investigated according to the presence of cancer during 2009–2014. The concentration of CEA and AFP were determined by an electrochemiluminescence immunoassay from Roche Diagnostics e601GmbH and STK1 by a commercial kit based on an enhanced chemiluminescent dot blot assay. RESULTS: The cancer incident rate increased from 0.048/100,000 to 0.220/100,000. The most common types of tumors were those of the liver, cervix and lung. STK1 correlated to tumor growth rate, was more sensitive than CEA and AFP for discovering people with malignant tumors and more sensitive among people who had diagnosis of malignant tumor. STK1 was also a prognostic biomarker for death at 10–40 months follow-up, while CEA and AFP were not. A combination of these markers increased the sensitivity by about 30%. CONCLUSION: STK1 is a reliable biomarker for discovering people with malignant tumors in cancer screening. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|